Mozobil for stem cell transplant study
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests if adding Mozobil (a drug that helps release stem cells) before stem cell transplant can improve outcomes for people with multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma. If you are eligible, you will receive Mozobil along with standard stem cell mobilization medicines.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have multiple myeloma, Hodgkin's lymphoma, or non-Hodgkin lymphoma.
- You must have adequate heart, lung, liver, and kidney function as determined by tests.
- Your performance status must be at least 60% on a standard scale (Karnofsky scale).
- You must have already used a stem cell mobilization regimen that included G-CSF (filgrastim or a similar drug) with or without plerixafor.
- You must not have uncontrolled HIV, an uncontrolled bacterial infection, active central nervous system disease, or another cancer (except skin cancer that only needs local treatment).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study tests a carfilzomib-based treatment plan to help people with multiple myeloma collect enough stem cells for an autologous (using your own) stem cell transplant. It’s mainly about whether this mobilization approach works and is safe for you.
This trial tests adding siltuximab to standard melphalan chemotherapy before a stem cell transplant. It is for people with multiple myeloma who are 60 or older and having a transplant within the first year of diagnosis.
This trial tests whether doing your own stem cell transplant, followed by polatuzumab, can improve outcomes in people with specific B-cell non-Hodgkin or Hodgkin lymphomas that did not fully respond or has come back. It aims to add a targeted medicine after transplant to help control the lymphoma.
This trial tests a new drug, motixafortide, combined with a standard growth factor (G-CSF) to help collect stem cells for a transplant in people with multiple myeloma. It may be a good option if your myeloma is in remission and you have not had a stem cell transplant before.
This trial studies a specific type of radiation (helical tomotherapy) in people with multiple myeloma who are planning an autologous stem cell transplant. It may help the study team understand how safe and effective this approach is when used during transplant preparation.
This Phase 1 study tests a personalized (tailored) autologous stem cell transplant for people with multiple myeloma or related plasma cell diseases. The goal is to see how safe it is and how well it works, using your own stem cells.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.